E-DRUG: The Medicines Patent Pool Extends Deadline for Feedback on Independent Feasibility Studies - Hepatitis C and Tuberculosis
---------------------------------
[Previous message posted 23 July. Moderator]
The Medicines Patent Pool has extended its deadline for stakeholder feedback on its two feasibility studies exploring the case for potential entry into hepatitis C and tuberculosis. The new deadline is August 28.
The MPP posted two independent studies on its website July 6 as part of its ongoing consultation process on the possibility of expanding into other disease areas. MPP commissioned Dalberg and the Center for Disease Analysis for the study on hepatitis C, and Trinity Partners and Elizabeth Gardiner to conduct the analysis for tuberculosis. The consultants were tasked with providing their own strategic assessment of whether and to what extent MPP’s model could be adapted to increase access to new and re-purposed products and promote innovation in these areas. MPP welcomes feedback from all stakeholders. Please send your comments on the reports or any other questions you might feel appropriate to consultation@medicinespatentpool.org<mailto:consultation@medicinespatentpool.org>. To read the feasibility studies, please click here: http://www.medicinespatentpool.org/mpp-releases-independent-feasibility-studies-on-hepc-and-tb/
Katie Moore
Medicines Patent Pool
www.medicinespatentpool.org